Genmab: Clinical Trials

30 recruiting, 24 terminated, 20 active not recruiting, 17 completed. 65 Phase 2, 46 Phase 1, 18 Phase 3, 2 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	65	Terminated 23, Recruiting 16, Completed 12, Active not recruiting 9, Withdrawn 3, Not yet recruiting 2
Phase 1	46	Terminated 19, Active not recruiting 9, Recruiting 9, Completed 8, Not yet recruiting 1
Phase 3	18	Active not recruiting 8, Recruiting 6, Completed 2, Not yet recruiting 1, Terminated 1
Phase 4	2	Completed 1, Recruiting 1

Follow Genmab: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma Epcoritamab, Observation - Randomized, Phase 2	Phase 2	Not yet recruiting	M.D. Anderson Cancer Center	40	2027-02-12	2026-09-23
Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma	Phase 1	Not yet recruiting	Jonsson Comprehensive Cancer Center	20	2026-12-08	2026-07-20
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian Cancer Rina-S, Bevacizumab - Ovarian Cancer	Phase 3	Not yet recruiting	Genmab	602	2026-11-01	2026-10-05
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2) Petosemtamab, Cetuximab, Bevacizumab - Colorectal Cancer	Phase 3	Recruiting	Genmab	600	2026-10-07	2026-10-09
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI Epcoritamab - CLL, CLL (Chronic Lymphocytic Leukemia)	Phase 2	Not yet recruiting	University of California, Irvine	24	2026-10-01	2026-09-14
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	688	2026-08-28	2026-10-07
A Phase 1 Trial of GEN1119 in Participants With Solid Tumors GEN1119 - Solid Tumours	Phase 1	Recruiting	Genmab	112	2026-08-13	2026-10-06
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer	Phase 3	Recruiting	Genmab	960	2026-08-11	2026-10-06
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer	Phase 3	Recruiting	Genmab	82	2026-06-26	2026-10-06
Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced Gastrointestinal (GI) Cancers Rina-S - Gastrointestinal Cancers	Phase 2	Recruiting	Genmab	160	2026-05-11	2026-10-06
A Study of GEN1106 in Participants With Solid Tumors GEN1106 - Solid Tumors, Urothelial Carcinoma	Phase 1	Recruiting	Genmab	103	2026-04-14	2026-10-06
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors GEN1079 - Advanced Solid Tumors	Phase 1	Recruiting	Genmab	121	2026-04-07	2026-09-09
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Rina-S, Bevacizumab - Ovarian Cancer, Platinum-sensitive Ovarian Cancer	Phase 3	Recruiting	Genmab	544	2026-04-03	2026-10-06
First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS) GEN3018 - R/R AML, R/R HR-MDS	Phase 1	Recruiting	Genmab	78	2026-02-16	2026-10-27
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer Rina-S - Non-small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	Genmab	240	2026-01-30	2026-10-06
Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse	Phase 2	Recruiting	University of Miami	26	2026-01-07	2026-10-15
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer Rina-S, IC - Endometrial Cancer, Recurrent or Progressive Endometrial Cancer	Phase 3	Recruiting	Genmab	660	2025-11-28	2026-10-06
Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) Epcoritamab - Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue	Phase 2	Recruiting	Izidore Lossos, MD	25	2025-10-13	2026-10-15
Study of Epcoritamab as a Consolidation Therapy in CLL/SLL Epcoritamab - CLL/SLL, CLL	Phase 2	Recruiting	Zulfa Omer	22	2025-08-22	2026-01-06
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma Epcoritamab, Lenalidomide, Tafasitamab - Lymphoma	Phase 2	Withdrawn	Memorial Sloan Kettering Cancer Center		2025-08-13	2026-04-07

Showing 20 of 100. Sign in to see all of them.

Conditions studied

Lymphoma, Large B-Cell, Diffuse (19)  ·  Ovarian Neoplasms (13)  ·  Carcinoma, Non-Small-Cell Lung (12)  ·  Lymphoma, Non-Hodgkin (12)  ·  Lymphoma, Follicular (11)  ·  Lymphoma (10)  ·  Neoplasms (10)  ·  Uterine Cervical Neoplasms (10)  ·  Recurrence (9)  ·  Endometrial Neoplasms (8)  ·  Head and Neck Neoplasms (7)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (7)  ·  Squamous Cell Carcinoma of Head and Neck (7)  ·  Colorectal Neoplasms (6)  ·  Fallopian Tube Neoplasms (5)

Interventions

Rituximab (13)  ·  pembrolizumab (13)  ·  Lenalidomide (11)  ·  Cyclophosphamide (10)  ·  Doxorubicin (10)  ·  Prednisone (10)  ·  Gemcitabine (9)  ·  tisotumab vedotin (9)  ·  zalutumumab (9)  ·  Vincristine (8)  ·  Bevacizumab (7)  ·  Carboplatin (7)  ·  Oxaliplatin (5)  ·  Cisplatin (4)  ·  Paclitaxel (4)

Countries

United States (75)  ·  Spain (42)  ·  Belgium (32)  ·  United Kingdom (30)  ·  France (29)  ·  Denmark (26)  ·  Italy (26)  ·  Japan (26)  ·  Netherlands (21)  ·  Germany (20)  ·  Poland (19)  ·  Australia (17)  ·  Czechia (16)  ·  Canada (15)  ·  South Korea (15)

Top investigators

Johann de Bono, Professor (2)  ·  Reid Merryman, MD (2)  ·  Catherine C Coombs, MD (1)  ·  Dai Chihara, MD (1)  ·  Dipenkumar Modi, MD (1)  ·  Elise Chong, MD (1)  ·  Gottfried von Keudell, MD (1)  ·  Gottfried von Keudell, MD, PhD (1)  ·  Hassan Aladdin, ICTM (1)  ·  Ignace Vergote, Professor (1)

Results publications

PMID 41044356, PMID 37496366, PMID 42411504, PMID 42541678, PMID 17602769, PMID 21377930, PMID 24714973, PMID 26377300, PMID 30745090, PMID 31796521, PMID 33845034, PMID 34508654, PMID 35176764, PMID 35633184, PMID 35688554, PMID 36548927, PMID 37651655, PMID 38151388, PMID 38528445, PMID 38889737, PMID 38959480, PMID 39322711, PMID 39792928, PMID 40319227, PMID 40347227, PMID 40472301, PMID 40550489, PMID 40632620, PMID 40920572, PMID 41371238, PMID 41380698, PMID 41644383, PMID 41784015, PMID 42000372, PMID 42285113, PMID 42431612, PMID 42622258, PMID 42660129, PMID 42680635

NIH funding

2023 (18), 2025 (9), 2017 (3), 2018 (2), 2019 (2), 2016 (1), R01CA308586 (1)